Phase I open-label, multicenter, dose-escalation clinical study of the initial safety and pharmacokinetic profiles of intravenous administration of SNS-595 [voreloxin] in patients with advanced malignancies
Latest Information Update: 25 Jul 2007
At a glance
- Drugs Vosaroxin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 06 Sep 2005 New trial record.